CountryFocus Healthcare Regulatory and Reimbursement Landscape
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>CountryFocus</strong>: <strong>Healthcare</strong>, <strong>Regulatory</strong> <strong>and</strong><br />
<strong>Reimbursement</strong> L<strong>and</strong>scape – China Is Released<br />
<strong>CountryFocus</strong>: <strong>Healthcare</strong>, <strong>Regulatory</strong> <strong>and</strong> <strong>Reimbursement</strong> L<strong>and</strong>scape - China Summary GlobalData, the<br />
industry analysis specialist, has released its latest report, <strong>CountryFocus</strong>: <strong>Healthcare</strong>, <strong>Regulatory</strong> <strong>and</strong><br />
<strong>Reimbursement</strong> L<strong>and</strong>scape – China.<br />
The report is an essential source of information on <strong>and</strong> analysis of the healthcare, regulatory <strong>and</strong><br />
reimbursement l<strong>and</strong>scape in China. It identifies the key trends in the countrys healthcare market <strong>and</strong><br />
provides insights into its demographic, regulatory, <strong>and</strong> reimbursement l<strong>and</strong>scape <strong>and</strong> healthcare<br />
infrastructure. The population of China in 2014 was approximately 1.37 billion, having grown at a<br />
Compound Annual Growth Rate (CAGR) of 0.5% from 2008. The countrys increasingly elderly population<br />
<strong>and</strong> a corresponding increase in the incidence of chronic diseases will help to boost the growth of the<br />
pharmaceutical industry, which was estimated to be worth $106.5 billion in 2008 <strong>and</strong> is projected to<br />
reach $1,637.3 billion by 2020, at a CAGR of 25.6%. Approximately 95% of China s population has<br />
healthcare coverage. Improvements in drug safety <strong>and</strong> quality; a shorter drug registration timeline; the<br />
elimination of price caps by the government; a more transparent system for the approval of drugs <strong>and</strong><br />
medical instruments; <strong>and</strong> an IPR regime are driving innovation in the pharmaceutical sector. These<br />
changes encourage foreign Multinational Companies (MNC) to invest in China. The Chinese medical<br />
device market is the second largest in Asia, valued at $27.7 billion in 2014 <strong>and</strong> projected to grow at a<br />
CAGR of 10.6% to an estimated $50.8 billion in 2020.<br />
These growth trends can be primarily attributed to the following causes - - Sedentary lifestyles leading<br />
to a high chronic disease burden. - The accessibility of healthcare professionals in the remote areas of<br />
the county. Scope The report provides information on the healthcare, regulatory, <strong>and</strong> reimbursement<br />
l<strong>and</strong>scape in China, <strong>and</strong> includes - - An overview of the pharmaceutical <strong>and</strong> medical device markets,<br />
comprising market size, segmentation, <strong>and</strong> key drivers <strong>and</strong> barriers - Profiles <strong>and</strong> SWOT analyses of the<br />
major players in the pharmaceutical market: GlaxoSmithKline, Pfizer, AstraZeneca, Harbin<br />
Pharmaceutical Group <strong>and</strong> Tianjin Tasly Pharmaceutical; <strong>and</strong> profiles <strong>and</strong> SWOT analyses of the major<br />
players in the medical device market: Siemens <strong>Healthcare</strong>, GE <strong>Healthcare</strong>, Philips, Medtronic <strong>and</strong> F.<br />
Hoffman La Roche - Insightful review of the reimbursement <strong>and</strong> regulatory l<strong>and</strong>scape, with analysis<br />
covering details of the countrys healthcare reimbursement process, regulatory agencies <strong>and</strong> the<br />
approval processes for new drugs <strong>and</strong> medical devices - Detailed analysis of the political <strong>and</strong> economic<br />
environment, covering economic indicators, demographics, healthcare infrastructure <strong>and</strong> healthcare<br />
expenditure - An overview of the opportunities for <strong>and</strong> challenges to growth in the healthcare market<br />
Reasons to buy This report will enhance your decision-making capability by allowing you to - - Develop<br />
business strategies by underst<strong>and</strong>ing the trends shaping <strong>and</strong> driving Chinas healthcare market - Drive<br />
revenues by underst<strong>and</strong>ing the key trends, reimbursement <strong>and</strong> regulatory policies, pharmaceutical<br />
market segments, <strong>and</strong> companies likely to affect Chinas healthcare market in the future - Formulate<br />
effective sales <strong>and</strong> marketing strategies by underst<strong>and</strong>ing the competitive l<strong>and</strong>scape <strong>and</strong> analyzing the<br />
performance of various competitors - Organize your sales <strong>and</strong> marketing efforts by identifying the<br />
market categories <strong>and</strong> segments that present the best opportunities for consolidation, investment, <strong>and</strong><br />
strategic partnerships - Identify, underst<strong>and</strong>, <strong>and</strong> capitalize on the opportunities <strong>and</strong> challenges in<br />
Chinas healthcare market<br />
1
Browse Complete Report with TOC @ http://www.idatainsights.com/reports-l<strong>and</strong>ingpage.php?id=197217/countryfocus-healthcare-regulatory-<strong>and</strong>-reimbursement-l<strong>and</strong>scape-china<br />
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-l<strong>and</strong>ingpage.php?id=197217/countryfocus-healthcare-regulatory-<strong>and</strong>-reimbursement-l<strong>and</strong>scape-china<br />
Table of Contents<br />
1 Table of Contents<br />
1 Table of Contents 8<br />
1.1 List of Tables 11<br />
1.2 List of Figures 15<br />
2 Introduction 19<br />
2.1 GlobalData Report Guidance 19<br />
3 Overview of Pharmaceutical <strong>and</strong> Medical Device Markets 20<br />
3.1 Pharmaceutical Market 20<br />
3.1.1 Market Overview 20<br />
3.1.2 Pharmaceutical Exports <strong>and</strong> Imports 24<br />
3.1.3 Supply Channels 25<br />
3.1.4 Market Segments 26<br />
3.1.5 Overview of Top Five Disease Areas 27<br />
3.1.6 Major Players 30<br />
3.2 Medical Device Market 63<br />
3.2.1 Market Overview 63<br />
3.2.2 Overview of Top Five Segments 65<br />
3.2.3 Diagnostic Market 81<br />
3.2.4 Major Players 84<br />
3.3 Market Drivers <strong>and</strong> Barriers 112<br />
3.3.1 Drivers 112<br />
3.3.2 Barriers 114<br />
4 Market Access 115<br />
4.1 Overview of the <strong>Healthcare</strong> System 115<br />
4.2 <strong>Reimbursement</strong> <strong>and</strong> Payer L<strong>and</strong>scape 115<br />
4.2.1 <strong>Reimbursement</strong> Process 115<br />
4.2.2 Overview of Insurance Providers 117<br />
4.2.3 Patient Share in <strong>Healthcare</strong> Spending 117<br />
4.2.4 Prescription Drug Price Trend 119<br />
4.2.5 Pricing Policies 120<br />
4.3 <strong>Regulatory</strong> L<strong>and</strong>scape 120<br />
4.3.1 Overview of <strong>Regulatory</strong> Agencies 120<br />
4.3.2 Market Authorization Procedure for Pharmaceutical Products 122<br />
4.3.3 Market Authorization Procedure for Medical Devices 125<br />
4.3.4 Licensing Process for Pharmaceutical <strong>and</strong> Medical Device Manufacturing 129<br />
4.3.5 Licensing Process for Pharmaceutical Exports <strong>and</strong> Imports 131<br />
4.3.6 Intellectual Property Rights 132<br />
4.3.7 Clinical Trial Regulations 134<br />
4.3.8 Pharmaceutical Advertising Regulations 135<br />
4.3.9 Pharmacy Regulations 136<br />
2
4.3.10 Labeling <strong>and</strong> Packaging Regulations 137<br />
5 Country Analysis 139<br />
5.1 Political Environment 139<br />
5.1.1 Political Structure 139<br />
5.1.2 Analysis of the Current Political Environment 140<br />
5.1.3 <strong>Healthcare</strong> Policy Initiatives 141<br />
5.2 Economic L<strong>and</strong>scape 143<br />
5.3 Economic Indicators 148<br />
5.3.1 Gross Domestic Product 148<br />
5.3.2 Gross National Income 151<br />
5.3.3 Inflation 152<br />
5.3.4 Currency Exchange Rate 155<br />
5.3.5 Foreign Direct Investment 156<br />
5.3.6 Foreign Exchange Reserves 157<br />
5.3.7 Trade Balance 159<br />
5.3.8 General Government Structural Balance 162<br />
5.3.9 General Government Gross Debt 163<br />
5.3.10 Major Industries 164<br />
5.4 Demographics 166<br />
5.4.1 Population 166<br />
5.4.2 Education <strong>and</strong> Literacy Rate 181<br />
5.4.3 Employment 183<br />
5.4.4 Disease Burden 184<br />
5.5 <strong>Healthcare</strong> Infrastructure 188<br />
5.5.1 Hospitals 188<br />
5.5.2 <strong>Healthcare</strong> Facilities 189<br />
5.5.3 <strong>Healthcare</strong> Parameters 191<br />
5.5.4 Environmental Health 193<br />
5.5.5 <strong>Healthcare</strong> Personnel 197<br />
5.6 <strong>Healthcare</strong> Expenditure 198<br />
5.6.1 Overview 198<br />
5.6.2 Public <strong>and</strong> Private Sector Share 200<br />
5.7 Trade Associations 201<br />
5.7.1 China Chamber of Commerce for Import <strong>and</strong> Export of Medicines <strong>and</strong> Health Products 201<br />
5.7.2 China <strong>Healthcare</strong> Association 201<br />
5.7.3 Shanghai Medical Instrument Trade Association 201<br />
5.7.4 Chinese Hospital Association 201<br />
5.7.5 China Pharmaceutical Industry Association 202<br />
5.8 Trade Fairs 202<br />
6 Opportunities <strong>and</strong> Challenges 203<br />
6.1 Opportunities 203<br />
6.2 Challenges 204<br />
7 Appendix 206<br />
7.1 Abbreviations 206<br />
7.2 Bibliography 209<br />
7.3 Research Methodology 219<br />
7.3.1 Coverage 219<br />
3
7.3.2 Secondary Research 220<br />
7.3.3 Forecasts 220<br />
7.3.4 Expert Panel 220<br />
7.4 Disclaimer 221<br />
Read More http://www.idatainsights.com/reports-l<strong>and</strong>ing-page.php?id=197217/countryfocushealthcare-regulatory-<strong>and</strong>-reimbursement-l<strong>and</strong>scape-china<br />
About Us:<br />
iData Insights which operates under Precision Research <strong>and</strong> Consulting Private Limited is a leading<br />
market research information aggregator <strong>and</strong> marketing research consulting firm. We conduct both<br />
primary <strong>and</strong> secondary research. Our work does not end with research it is also involved in distributing<br />
reports for different companies . We provide actionable recommendations <strong>and</strong> provide our expertise for<br />
business success today <strong>and</strong> tomorrow. It is our goal to be a partner to our clients in the exploration <strong>and</strong><br />
discovery, <strong>and</strong> then be their guide in the implementation of changes that will make a difference to their<br />
bottom line.<br />
ContactUs:<br />
iData Insights<br />
Tel: 1-866-237-2965<br />
Web: http://www.idatainsights.com<br />
Email: info@idatainsights.com<br />
About iData Insights<br />
We work around the clock until our clients are completely satisfied with their promised results. It is our<br />
mission to provide timely services coupled with acute client care to create a long-lasting relationship<br />
with you. We deliver on our promise to provide results that are essential to the success of your<br />
company. We believe that by doing so, we will earn the trust of our clients for future projects<br />
4
Change language